Featured Research

from universities, journals, and other organizations

Cancer and the Goldilocks Effect: Too much or too little of an enzyme promotes cancer

Date:
April 3, 2014
Source:
University of California, San Diego Health Sciences
Summary:
Too little or too much of an enzyme called SRPK1 promotes cancer by disrupting a regulatory event critical for many fundamental cellular processes, including proliferation, research has found. "To my knowledge, this is the first time it has been shown that a signal kinase behaves as a tumor suppressor or a promoter, depending upon its abundance in the same cell" said one researcher. "The point is that too much or too little are both bad."

Researchers at the University of California, San Diego School of Medicine have found that too little or too much of an enzyme called SRPK1 promotes cancer by disrupting a regulatory event critical for many fundamental cellular processes, including proliferation.

The findings are published in the current online issue of Molecular Cell.

The family of SRPK kinases was first discovered by Xiang-Dong Fu, PhD, professor in the Department of Cellular and Molecular Medicine at UC San Diego in 1994. In 2012, Fu and colleagues uncovered that SPRK1 was a key signal transducer devoted to regulating alternative pre-mRNA splicing, a process that allows a single gene to produce multiple mRNA isoforms, which in many cases encode functionally distinct proteins. In this pathway, SRPK1 was a downstream target of Akt, also known as protein kinase B. Akt- activated SRPK1 moves to the nucleus to induce its targeted splicing factors.

In their latest paper, Fu and colleagues report that SRPK1 was found to act as a tumor suppressor because when ablated or removed from mouse embryonic fibroblasts, unwanted cell transformation occurred. Unexpectedly, when SRPK1 was overexpressed in mouse cells, tumor development also happened.

"To my knowledge, this is the first time it has been shown that a signal kinase behaves as a tumor suppressor or a promoter, depending upon its abundance in the same cell" said Fu. "The point is that too much or too little are both bad."

Such contrary phenomena are due to a surprising role of SRPK1 in regulating the activity of Akt via a specific Akt phosphatase discovered earlier by Alexandra C. Newton, PhD, professor of pharmacology at UC San Diego. The Akt phosphatase cannot find Akt when there is too little SRPK1 to assist, and the phosphatase is tied up when there is too much SRPK1. In both cases, the result is a dampening of Akt inactivation.

As Akt plays a key role in many cellular processes, such as glucose metabolism, apoptosis, proliferation and all key aspects of tumor development, the elucidated mechanism provides a critical insight into tumorigenesis in humans. Indeed, compared to normal cells, many tumors show SRPK1 overexpression while others display reduced expression.

The findings may have future therapeutic implications, but Fu said the challenges remain daunting. "Most tumors show SRPK1 overexpression, so it may be possible to treat certain cancers with a specific SRPK1 inhibitor. This has been already demonstrated by others. But suppressing a cancer not related to SRPK1 overexpression could actually stimulate that cancer."


Story Source:

The above story is based on materials provided by University of California, San Diego Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. Pingping Wang, Zhihong Zhou, Anchang Hu, Claudio PontedeAlbuquerque, Yu Zhou, Lixin Hong, Emma Sierecki, Masahiko Ajiro, Michael Kruhlak, Curtis Harris, Kun-Liang Guan, Zhi-Ming Zheng, AlexandraC. Newton, Peiqing Sun, Huilin Zhou, Xiang-Dong Fu. Both Decreased and Increased SRPK1 Levels Promote Cancer by Interfering with PHLPP-Mediated Dephosphorylation of Akt. Molecular Cell, 2014; DOI: 10.1016/j.molcel.2014.03.007

Cite This Page:

University of California, San Diego Health Sciences. "Cancer and the Goldilocks Effect: Too much or too little of an enzyme promotes cancer." ScienceDaily. ScienceDaily, 3 April 2014. <www.sciencedaily.com/releases/2014/04/140403131742.htm>.
University of California, San Diego Health Sciences. (2014, April 3). Cancer and the Goldilocks Effect: Too much or too little of an enzyme promotes cancer. ScienceDaily. Retrieved September 30, 2014 from www.sciencedaily.com/releases/2014/04/140403131742.htm
University of California, San Diego Health Sciences. "Cancer and the Goldilocks Effect: Too much or too little of an enzyme promotes cancer." ScienceDaily. www.sciencedaily.com/releases/2014/04/140403131742.htm (accessed September 30, 2014).

Share This



More Health & Medicine News

Tuesday, September 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins